MX2011007647A - Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. - Google Patents
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.Info
- Publication number
- MX2011007647A MX2011007647A MX2011007647A MX2011007647A MX2011007647A MX 2011007647 A MX2011007647 A MX 2011007647A MX 2011007647 A MX2011007647 A MX 2011007647A MX 2011007647 A MX2011007647 A MX 2011007647A MX 2011007647 A MX2011007647 A MX 2011007647A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- autoimmune diseases
- treating inflammatory
- immunosuppressive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente invención se relaciona con moléculas inmunosupresoras que incluyen las variantes de IL-2 inmunosupresoras, y con el uso de tales moléculas para tratar trastornos inflamatorios y autoinmunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14611109P | 2009-01-21 | 2009-01-21 | |
PCT/US2010/021519 WO2010085495A1 (en) | 2009-01-21 | 2010-01-20 | Compositions and methods of treating inflammatory and autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011007647A true MX2011007647A (es) | 2011-09-01 |
Family
ID=42356180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011007647A MX2011007647A (es) | 2009-01-21 | 2010-01-20 | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
Country Status (8)
Country | Link |
---|---|
US (4) | US20110274650A1 (es) |
EP (1) | EP2382228B1 (es) |
JP (6) | JP5766124B2 (es) |
AU (1) | AU2010206840B2 (es) |
CA (1) | CA2749539C (es) |
ES (1) | ES2825173T3 (es) |
MX (1) | MX2011007647A (es) |
WO (1) | WO2010085495A1 (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
EP3971206A1 (en) | 2011-02-10 | 2022-03-23 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
EP3766513A1 (en) | 2011-03-11 | 2021-01-20 | Assistance Publique Hôpitaux de Paris | Use of low dosage il-2 for treating vasculitis |
BR112013023151A2 (pt) | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US9481866B2 (en) * | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
CA2925421C (en) | 2013-09-24 | 2023-08-29 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
CA2931114A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
CA2954847A1 (en) * | 2014-07-21 | 2016-01-28 | Jeffrey Greve | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
EP3180020B1 (en) * | 2014-08-11 | 2018-12-26 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CR20170510A (es) * | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
CA2982362A1 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
WO2016164937A2 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
EP3458096A4 (en) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
CA3054955A1 (en) | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
US20200131555A1 (en) | 2017-07-11 | 2020-04-30 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
SG11202000939PA (en) * | 2017-08-03 | 2020-02-27 | Synthorx Inc | Cytokine conjugates for the treatment of proliferative and infectious diseases |
JP2021500855A (ja) * | 2017-09-07 | 2021-01-14 | キュー バイオファーマ, インコーポレイテッド | 抗原提示ポリペプチドおよびその使用方法 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
CN111655718A (zh) * | 2017-12-19 | 2020-09-11 | Xencor股份有限公司 | 经过工程化的il-2 fc融合蛋白 |
CN111868079A (zh) * | 2017-12-27 | 2020-10-30 | 协和麒麟株式会社 | Il-2变体 |
CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
US11534479B2 (en) | 2018-02-16 | 2022-12-27 | Iltoo Pharma | Use of interleukin 2 for treating Sjögren's syndrome |
CN113166220A (zh) | 2018-03-09 | 2021-07-23 | 奥美药业有限公司 | 创新细胞因子前药 |
CN112154153A (zh) | 2018-03-28 | 2020-12-29 | 百时美施贵宝公司 | 白介素-2/白介素-2受体α融合蛋白以及使用方法 |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
TW202034945A (zh) | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
KR20210123299A (ko) | 2019-02-06 | 2021-10-13 | 신톡스, 인크. | Il-2 콘쥬게이트 및 이의 사용 방법 |
WO2020168059A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
CN113661175A (zh) | 2019-02-15 | 2021-11-16 | 整体分子公司 | 包含共同轻链的抗体及其用途 |
EP3946424A1 (en) | 2019-03-29 | 2022-02-09 | Institut Curie | Interleukin-2 variants with modified biological activity |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
US20220289807A1 (en) | 2019-08-13 | 2022-09-15 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
IL293628A (en) | 2019-12-12 | 2022-08-01 | Iltoo Pharma | Interleukin 2 chimeric structures |
IL293471A (en) | 2019-12-17 | 2022-08-01 | Amgen Inc | Dual interleukin-2 / tnf receptor agonist for use in medicine |
CN115023444A (zh) | 2019-12-20 | 2022-09-06 | 再生元制药公司 | 新型il2激动剂及其使用方法 |
JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾il-2ポリペプチドおよびその使用 |
JP7303391B2 (ja) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | バイアス型il2ムテイン、方法、および組成物 |
US11827684B2 (en) | 2020-04-22 | 2023-11-28 | Merck Sharp & Dohme Llc | Human interleukin-2 conjugates biased for the interleukin-2 receptor beta GAMMAc dimer and conjugated to a nonpeptidic, water-soluble polymer |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
CA3178074A1 (en) | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Il-2 sequences and uses thereof |
CA3189291A1 (en) * | 2020-07-14 | 2022-01-20 | Pfizer Inc. | Recombinant vaccinia virus |
TW202219060A (zh) * | 2020-08-28 | 2022-05-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 醣基化il-2蛋白及其用途 |
CA3195260A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN112279906B (zh) * | 2020-10-30 | 2022-09-20 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其制备方法与应用 |
KR20230107598A (ko) | 2020-11-13 | 2023-07-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 인간 인터루킨 2 변이체 또는 이의 유도체를 포함하는 약학적 조성물 및 이의 용도 |
CA3203977A1 (en) * | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
AU2022306145A1 (en) | 2021-07-09 | 2024-02-01 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
US20230183331A1 (en) * | 2021-07-09 | 2023-06-15 | Bright Peak Therapeutics Ag | Modified tnf-alpha antibodies and uses thereof |
KR20240036511A (ko) | 2021-07-30 | 2024-03-20 | 윈취안 바이오테크놀로지 (베이징) 씨오., 엘티디. | 인간 인터루킨-2 변이체 및 이의 용도 |
WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4470461A (en) | 1982-09-30 | 1984-09-11 | Phillips Petroleum Company | Organic nitro compounds as cosurfactants in enhanced oil recovery processes |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
EP0262802A3 (en) | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
AU627477B2 (en) | 1988-07-05 | 1992-08-27 | Amgen, Inc. | Interleukin ii analogs |
CA2062582C (en) | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
EP1476180A4 (en) | 2001-08-13 | 2005-04-20 | Univ Southern California | INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY |
AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
AR043504A1 (es) * | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
WO2005091956A2 (en) | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
AU2006232374B2 (en) * | 2005-04-01 | 2011-08-25 | University Of Southern California | Preventing rejection of transplanted tissue using regulatory T cells |
CA2642532A1 (en) | 2006-02-16 | 2007-08-23 | Nascent Biologics, Inc. | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject |
EP1988921A4 (en) | 2006-02-28 | 2010-02-10 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB |
WO2008003473A2 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
CN101479570A (zh) | 2006-07-06 | 2009-07-08 | 三菱电机株式会社 | 导航装置 |
WO2008112325A2 (en) | 2007-03-15 | 2008-09-18 | Biogen Idec Ma Inc. | Treatment of autoimmune disorders |
GB0623539D0 (en) | 2006-11-24 | 2007-01-03 | Avidex Ltd | Polypeptides |
JP2010518873A (ja) | 2007-02-27 | 2010-06-03 | ジェネンテック, インコーポレイテッド | アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用 |
WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
WO2010017220A1 (en) | 2008-08-04 | 2010-02-11 | The Trustees Of The University Of Pennsylvania | Methods for expanding regulatory t-cells |
US20110200534A1 (en) | 2008-08-21 | 2011-08-18 | Industry-Academic Cooperation Foundation, Yonsei U | T1-T2 Dual Modal MRI Contrast Agents |
WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
EP3766513A1 (en) | 2011-03-11 | 2021-01-20 | Assistance Publique Hôpitaux de Paris | Use of low dosage il-2 for treating vasculitis |
WO2012125850A1 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Fc variants |
-
2010
- 2010-01-20 WO PCT/US2010/021519 patent/WO2010085495A1/en active Application Filing
- 2010-01-20 EP EP10733814.7A patent/EP2382228B1/en active Active
- 2010-01-20 AU AU2010206840A patent/AU2010206840B2/en active Active
- 2010-01-20 ES ES10733814T patent/ES2825173T3/es active Active
- 2010-01-20 JP JP2011548074A patent/JP5766124B2/ja active Active
- 2010-01-20 US US13/145,537 patent/US20110274650A1/en not_active Abandoned
- 2010-01-20 CA CA2749539A patent/CA2749539C/en active Active
- 2010-01-20 MX MX2011007647A patent/MX2011007647A/es active IP Right Grant
-
2012
- 2012-11-08 US US13/672,417 patent/US9732134B2/en active Active
-
2014
- 2014-04-15 JP JP2014083388A patent/JP2014133756A/ja not_active Withdrawn
-
2016
- 2016-05-06 JP JP2016092985A patent/JP2016138140A/ja not_active Withdrawn
-
2017
- 2017-07-13 US US15/649,520 patent/US11560415B2/en active Active
-
2018
- 2018-02-26 JP JP2018031926A patent/JP2018087244A/ja not_active Withdrawn
-
2019
- 2019-10-18 JP JP2019191112A patent/JP2020023550A/ja not_active Withdrawn
-
2021
- 2021-09-03 JP JP2021143804A patent/JP2021185191A/ja active Pending
-
2022
- 2022-12-20 US US18/068,970 patent/US20230139534A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2010085495A1 (en) | 2010-07-29 |
JP5766124B2 (ja) | 2015-08-19 |
US11560415B2 (en) | 2023-01-24 |
EP2382228A4 (en) | 2013-01-09 |
US20110274650A1 (en) | 2011-11-10 |
EP2382228A1 (en) | 2011-11-02 |
CA2749539C (en) | 2022-07-19 |
JP2020023550A (ja) | 2020-02-13 |
US20230139534A1 (en) | 2023-05-04 |
EP2382228B1 (en) | 2020-08-26 |
ES2825173T3 (es) | 2021-05-14 |
US9732134B2 (en) | 2017-08-15 |
JP2018087244A (ja) | 2018-06-07 |
JP2012515778A (ja) | 2012-07-12 |
JP2014133756A (ja) | 2014-07-24 |
AU2010206840B2 (en) | 2015-02-05 |
AU2010206840A1 (en) | 2011-07-21 |
JP2021185191A (ja) | 2021-12-09 |
JP2016138140A (ja) | 2016-08-04 |
US20170313753A1 (en) | 2017-11-02 |
CA2749539A1 (en) | 2010-07-29 |
US20130195795A1 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007647A (es) | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
MY165582A (en) | Azetidine and cyclobutane derivatives as jak inhibitors | |
AU2016204346A1 (en) | Methods and compositions for cell-proliferation-related disorders | |
MX2009009079A (es) | Anticuerpos anti-il-23p19 de ingenieria. | |
MX2009009080A (es) | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. | |
PH12015502575B1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
MX2009009283A (es) | Anticuerpos anti-interleuquina -23r de ingenieria. | |
EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
TW200800994A (en) | Inhibitors of E1 activating enzymes | |
IN2012DN02471A (es) | ||
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
MX2010000098A (es) | Derivados de guanina policiclicos y sus metodos de uso. | |
MX2011009033A (es) | Inhibidores triciclicos de cinasa pirazolopiridina. | |
EP2558124A4 (en) | POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION | |
EA201171435A1 (ru) | Твердые фармацевтические композиции и способы их получения | |
MX2015003701A (es) | Composiciones para tratamiento. | |
MX2009009190A (es) | Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean. | |
MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
MY151104A (en) | Novel use | |
WO2012061390A3 (en) | Therapeutic compositions and methods | |
EP4070794A3 (en) | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders | |
WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |